ViewRay, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul Ziegler Jr.,
- Full Time Employees
- 295
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 2 Thermo Fisher Way Oakwood OH United States of America 44146
- IPO Date
- Aug 10, 2015
- CIK
- 0001597313
- Website
- viewray.com
- Similar Companies
- Business
- ViewRay Systems, Inc. designs, manufactures and markets the MRIdian A3i Radiation Therapy System, an MRI-guided adaptive radiotherapy platform that integrates high-definition MRI imaging, precise radiation delivery and proprietary software to visualize, target and treat soft-tissue tumors in real time while minimizing exposure to surrounding healthy tissue; the system supports treatments for prostate, pancreas, liver, lung, breast and oligometastatic cancers, among others, and fits standard radiation therapy vaults without structural modifications. Founded in 2004 and originally headquartered in Oakwood Village, Ohio, with later operations referenced in Denver, Colorado, the company serves university research hospitals, community hospitals, private practices, government institutions and freestanding cancer centers across the United States, Italy, France, Taiwan, the United Kingdom and other international markets through direct sales and distributors. In July 2023, predecessor ViewRay, Inc. (NASDAQ: VRAY) filed for Chapter 11 bankruptcy reorganization, which converted to Chapter 7 liquidation in October 2023, followed by Nasdaq delisting and OTC trading under VRAYQ; ViewRay Systems, Inc. emerged as a new privately held entity on February 6, 2024, acquiring all assets of the original company including intellectual property, inventory, software, quality management systems and technical documentation to continue operations and commercialization of the MRIdian A3i system.
Open Letter to ViewRay Customers, Service, Software Engineers and Suppliers—Let's Preserve ViewRay Technology
Letter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies
Open Letter to ViewRay Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies
ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets
Why Is ViewRay (VRAY) Stock Down 69% Today?
ViewRay® Files Voluntary Chapter 11 Petitions
VA Oklahoma City Healthcare System Chooses ViewRay's MRIdian® MRI-Guided Radiation Therapy System
Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)
ViewRay's MRIdian® to be Featured at Leading European Radiation Oncology Meeting
ViewRay (VRAY) Reports Q1 Loss, Misses Revenue Estimates
ViewRay Announces First Quarter 2023 Results
ViewRay: Shares Crater As Company Warns Of Slower Growth, Higher Cash Burn
ViewRay Announces Preliminary First Quarter 2023 Results and Updated Fiscal Year 2023 Financial Guidance; Company to Explore Strategic Alternatives to Maximize Shareholder Value
ViewRay Announces Conference Call for Preliminary First Quarter 2023 Financial Results to be held Pre-Market opening on April 13, 2023
Penny Stocks To Buy Now? 7 With Unusual Options Volume This Week
GenesisCare Launches ViewRay MRIdian® MRI-Guided Radiation Therapy System at Lee Health Regional Cancer Center, Empowering Cancer Patient Care with an Innovative Radiotherapy Approach with Reduced Side Effects, Fewer Sessions Needed
Military University Hospital Prague Selects ViewRay's MRIdian® MRI-Guided Radiation Therapy System to Treat Cancer Patients
Siteman Cancer Center at Washington University Treats 2,000th Patient with MRIdian® MRI-Guided Radiation Therapy
ViewRay, Inc. (VRAY) Q4 2022 Earnings Call Transcript
ViewRay (VRAY) Reports Q4 Loss, Misses Revenue Estimates